Protocol Ledger

NCT07867080 · Phase III · RECRUITING

A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

Interventional Phase III clinical trial protocol NCT07867080 sponsored by 4D Molecular Therapeutics in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-18 Enrollment: 514 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07867080
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)514 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07867080
Protocol FieldVerified Registry Value
NCT IdentifierNCT07867080
Consolidated Lead Sponsor4D Molecular Therapeutics
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment514 participants (ESTIMATED)
Registered Start Date2026-09-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07867080
Hospital Research SiteLocationSite Profile
The Retina PartnersEncino, CAOpen Hospital Dossier ->
Retina Consultants of Orange CountyFullerton, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI